Combination Treatment with Decitabine Yields Higher Response for Patients with AML or MDS
PHILADELPHIA (December 7, 2015) – The combination of an epigenetic agent with arsenic trioxide may be a potential treatment for patients diagnosed with advanced myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who cannot undergo intense chemotherapy. Fox Chase Cancer Center – Temple Health researchers presented the results of a phase 2 trial at the 2015 American Society of Hematology Annual Meeting in December 2015.